︎    ︎    ︎    

Bruno Silva-Santos, PhD

Professor @Faculdade de Medicina da Universidade de Lisboa

Group Leader & Vice-Director @Instituto de Medicina Molecular (iMM)

Lisbon, Portugal

Bruno Silva-Santos is a Group Leader and Vice-Director of Instituto de Medicina Molecular (iMM), and Associate Professor and Director of Immuno-Oncology at the Faculty of Medicine of the University of Lisbon (Portugal).

His research, which has been funded, among others, by the European Research Council and Fundación la Caixa, is mostly dedicated to gamma-delta T cells, having dissected novel molecular mechanisms of their differentiation and tumor cell recognition, published in over 100 papers in top international peer-reviewed journals.

In 2019, Bruno Silva-Santos was elected Member of European Molecular Organization (EMBO) in recognition of his scientific contributions. His translational work on Immuno-Oncology was further recognized with various awards and the nomination as Honorary Member of the European Academy of Tumor Immunology.

His work also constituted the basis for a start-up company (founded in 2013) focused on cancer immunotherapy, Lymphact, which was acquired in 2018 by the British biotech GammaDelta Therapeutics, and is now (2022) being incorporated (including the proprietary technology developed in the Silva-Santos lab and in Lymphact) in Takeda Pharmaceutical.

Visit the speaker’s lab here ︎

This symposium is supported by QuantOCancer Project funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement Nº 810653.